Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451

CODEN : IJCEKF

Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...

Article type

Original Article


Article page

174-177


Authors Details

Ramandeep Kaur, Sachin Walia, Harsimran Singh, Navreet Kaur


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 1398

PDF Downloaded: 487


To study the comparison of efficacy and side effect profile of bimatoprost 0.03% versus fixed combination timolol 0.5% and dorzolamide 2% in patients with primary open angle glaucoma or ocular hyperte


Original Article

Author Details : Ramandeep Kaur, Sachin Walia, Harsimran Singh, Navreet Kaur

Volume : 2, Issue : 3, Year : 2016

Article Page : 174-177


Suggest article by email

Get Permission

Abstract

Aims: To study IOP lowering efficacy and side effect profile of bimatoprost 0.03% versus fixed combination timolol 0.5% and dorzolamide 2%.
Settings and Design: Prospective, open, randomized, parallel group, comparative study, 100 patients of POAG/ocular hypertension with moderate glaucomatous damage attending the outpatient department of ophthalmology, at our institute were included.
Materials and Methods: The patients were randomly assigned to one of the two treatment groups, each having a sample size of 50 patients. Group 1 instilled 1 drop of Bimatoprost 0.03%at 8 p.m. (once daily) for 12 weeks and Group 2 instilled 1 drop of fixed drug combination of timolol 0.5% and dorzolamide 2% at 8a.m. and 1 drop at 8p.m. for 12 weeks. All the patients were subjected to the detailed ocular examination following examination and tests at baseline, 4 weeks, 8 weeks and 12 weeks after starting the study treatment.
Results: Both the groups showed comparable IOP reductions in the patients. There was no statistically significant difference in the mean IOP reduction among the two groups’ at all follow-up visits. The most frequently reported adverse effect was conjunctival hyperaemia in bimatoprost group and burning, stinging sensation in eyes and taste perversion in the DTFC group.
Conclusion: Bimatoprost can be used as a long term monotherapy agent in the treatment of POAG and ocular hypertension providing good efficacy with an easy dosing regimen and without much side effects.

Keywords: Bimatoprost, Timolol dorzolamide, Primary open angle glaucoma, Ocular hypertension


How to cite : Kaur R, Walia S, Singh H, Kaur N, To study the comparison of efficacy and side effect profile of bimatoprost 0.03% versus fixed combination timolol 0.5% and dorzolamide 2% in patients with primary open angle glaucoma or ocular hyperte. Indian J Clin Exp Ophthalmol 2016;2(3):174-177

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.